Occam Recruits Ruben Tommasi, PhD as Chief Scientific Officer for Entact Bio
In September 2024, Occam placed Ruben Tommasi, PhD, as Chief Scientific Officer at Entact Bio, a Qiming, venBio, and Abingworth investment. Entact, led by seasoned biotech entrepreneur Vicky Richon, is developing novel precision medicines that enhance the function of beneficial proteins.
Ruben brings three decades of experience in the life sciences industry, where his leadership drove drug discovery across therapeutic areas at global pharmaceutical companies and innovative biotechs.
Prior to Entact, Ruben held the Chief Scientific Officer role at both Dunad Therapeutics and Entasis Therapeutics. Previous roles include leadership positions at AstraZeneca and the Novartis Institutes for Biomedical Research (NIBR).
Occam Global is a biotech executive search, recruiting, and leadership advisory firm with specialties across technological fields, including Biotech, TechBio, AI-ML, Cell/Gene Therapy, Diagnostics/Genomics, Medical Devices, Research Tools, Digital Health, Alternative Energy, AgTech, EdTech, Robotics as well as adjacencies within Venture Capital and Private Equity. Occam helps build biotech executive leadership teams that meet the demands of the rapidly developing, competitive, and challenging industries it serves. Occam Global recruits leading C-Suite executives and board members for the most exciting and innovative clients across the world with a specific focus on the UK, Continental Europe, the US, and Asia.